Want to track SIGHTp and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
SIGHTp is not paying dividends to its shareholders.
The last earnings report, released on Mar 20, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on XPAR (EUR).
GenSight Biologics S.A. (SIGHTp) FAQ
On which exchange is it traded?
GenSight Biologics S.A. is listed on CBOE.
What is its stock symbol?
The ticker symbol is SIGHTp.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has GenSight Biologics S.A. ever had a stock split?
No, there has never been a stock split.
GenSight Biologics S.A. Profile
| Biotechnology Industry | Healthcare Sector | Laurence Rodriguez CEO | CBOE Exchange | FR0013183985 ISIN |
| FR Country | 16 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
GenSight Biologics S.A. is a clinical-stage biotechnology company focused on the discovery, development, and potential commercialization of innovative therapies for mitochondrial and neurodegenerative diseases, particularly those affecting the eye and central nervous system. Utilizing cutting-edge gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms, the company aims to address some of the most challenging medical conditions. Founded in 2012, GenSight Biologics is headquartered in Paris, France, reflecting its commitment to advancing healthcare through biotechnological innovations.
Products and Services
- LUMEVOQ (GS010): As the company's lead product candidate, LUMEVOQ is at the forefront of GenSight Biologics' innovative portfolio. This recombinant AAV2-based gene therapy is specifically designed to treat leber hereditary optic neuropathy (LHON), a condition caused by mutations in the ND4 gene. Currently, LUMEVOQ is progressing through Phase III clinical trials, demonstrating the company's commitment to addressing rare genetic disorders of the eye with cutting-edge gene therapy solutions.
- GS030: Representing another significant advancement in genSight's research endeavors, GS030 is in Phase I/II clinical trial aimed at treating retinitis pigmentosa. This product is a testament to the company's continuous exploration of the potential of gene therapy in curing not just one, but a series of degenerative eye diseases. Further, GS030 is also being studied in a preclinical setting for its application in treating dry age-related macular degeneration, showcasing the broad spectrum of GenSight's therapeutic ambitions.
- Preclinical Products for Ophthalmic and Neurodegenerative Diseases: In addition to its leading candidates, GenSight Biologics is actively engaged in the development of a pipeline of products targeting a range of ophthalmic and neurodegenerative diseases. Although these products are in the preclinical stage, their development underscores the company's dedication to leveraging its technological platforms to expand its impact on the healthcare industry, particularly in areas where treatment options are currently limited or non-existent.
Contact Information
Address: 74, rue du Faubourg Saint-Antoine
Phone: 33 1 76 21 72 20
Website: https://www.gensight-biologics.com
